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Testicular cancer: Management challenges in an African 
developing country
F O Ugwumba, A E Aghaji
Testicular cancer accounted for 1.1% of all cancers in males 
in the year 2000.1 The incidence was reported to be lower in 
non-whites than whites,2 while a study on a black population 
showed that, while there was a low incidence of germ cell 
tumours, non-germ cell tumours had a similar incidence to 
that in the white series.3 Testicular tumours arise from germ 
cells in 94 - 97% of cases. The tumours are classified into 
seminoma (classic, anaplastic and spermatocytic variants) and 
non-seminomatous germ cell tumours (embryonal carcinoma, 
teratocarcinoma, teratoma, choriocarcinoma, and yolk sac 
tumours). Non-germ cell tumours include gonadal stromal 
tumours and miscellaneous neoplasms.
The treatment of germ cell tumours has greatly evolved 
from extirpative surgery only, to cisplatin-based chemotherapy, 
radiotherapy and retroperitoneal lymph node dissection. 
These methods have now made the condition being potentially 
curable, with documentation of excellent survival figures in 
the developed world.4 However, in the developing world, 
treatment outcome is still poor.5,6 Reasons for this trend 
include lack of well-established first-line medical treatment 
that leads to late diagnosis and referral, and unavailability of 
treatment, poverty and reluctance to accept chemotherapy and 
radiotherapy.
We examined the presentation, outcome and challenges in 
the management of testicular cancer in Enugu, Nigeria.
Patients and methods
The University of Nigeria Teaching Hospital and JAMA 
Urological Clinic are major referral centres for patients with 
urological ailments, including tumours, in south-eastern 
Nigeria, which has a population of over 20 million people. 
Patients are referred from peripheral hospitals, and the general 
outpatient department and other clinical departments of 
the teaching hospital. Diagnosis of testicular tumours was 
made on clinical grounds (palpable testicular mass with or 
without abdominal mass), scrotal-abdominal ultrasonography, 
chest radiograph, intravenous urography and estimation 
of tumour markers (beta-human chorionic gonadotrophin 
(bHCG) and alpha-fetoprotein (AFP)). Computed tomography 
(CT) scanning was not done because it was not available 
during the study period. Clinical staging was according to 
the Royal Marsden staging system (Table I). All diagnoses 
were confirmed by histopathological analysis of the operative 
specimens. Between April 1984 and March 2003 (19 years), 
24 patients were managed in the two centres. Research ethics 
committee approval was obtained from both institutions 
for our study. Data for age at presentation, clinical features, 
investigation and stage of disease were collected. Also assessed 
were histological type, treatment given, duration of follow-up, 
special management problems, and outcome.
Data analysis was done by means of SPSS software, version 
15 (SPSS, Chicago, IL, USA).
Results
Twenty-four patients were seen in the study period; their ages 
ranged from 16 to 43 years (mean 28.1 years); 20 (83.3%) were 
<40 years old, while 4 (16.7%) were >40 years old (Fig. 1).
Clinical presentation
Twenty-three (96%) patients presented with intra-scrotal 
testicular masses; one presented with an undescended intra-
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Background. Advances in oncology have greatly improved 
the prognosis of testicular cancer. In developing countries, 
however, the outcome is still poor.
Patients and methods. Twenty-four patients managed for 
testicular cancer at two centres (University of Nigeria 
Teaching Hospital, Enugu, Nigeria, and JAMA Urological 
Clinic, Enugu) between April 1984 and March 2003 were 
prospectively studied. Histopathological data were obtained 
in all cases.
Results. Peak age incidence was 20 - 29 years. Testicular 
swelling was the principal complaint in 23 patients. The 
mean interval between onset of symptoms and presentation 
was 5.3 months. Two patients (8.3%) presented with stage 1 
disease, 7 (29.2%) with stage 2, 7 (29.2%) with stage 3, and 8 
(33.3%) with stage 4. Seventy-five per cent of tumours were 
right-sided, and 25% were left-sided. Treatment consisted 
of radical orchidectomy in all patients and cisplatin-based 
chemotherapy and radiotherapy in some patients. One 
patient with a tumour in an intra-abdominal testis underwent 
laparotomy. The most common histological types were 
seminoma and embryonal carcinoma. A fifth of the patients 
died, while half were lost to follow-up. The mean follow-up 
period was 9 months.
Conclusion. Morbidity and mortality of testicular cancer 
is high in developing countries. Late presentation, 
poverty, paucity of resources and the high cost of newer 
imaging modalities and treatment are major challenges to 
management. Better health funding and education regarding 
testicular self-examination is essential.
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abdominal testes mass. Most (75%) tumours were right-sided 
while 25% were left-sided (Fig. 2). The mean duration of 
symptoms before presentation was 5.3 months (range 1 - 
12 months). Presentations other than testicular mass were 
abdominal mass (9 – 38%), primary infertility (3 – 13%), 
gynaecomastia (6 – 25%) and undescended testes in 1 (4%) 
patient.
Evaluation
Following a full history and physical examination, scrotal-
abdominal ultrasonography, chest radiograph and intravenous 
urography were done. CT scanning was not available, which 
challenged our management as it limited the staging of 
retroperitoneal nodes. AFP was elevated in 3 patients, both 
AFP and BHCG were elevated in 16 patients, and both AFP 
and BHCG were negative in 5 patients. Most patients presented 
at stages 2, 3 and 4 (29%, 29% and 33% respectively (Table 
II). In the absence of CT imaging, we relied on abdominal 
ultrasonography to detect gross retroperitoneal lymph node 
involvement. As this is a poor substitute, many of our patients 
might have been understaged, which was an obvious limitation 
as staging accuracy of abdominal disease was suboptimal.
Cervical non-supraclavicular lymph node involvement 
was seen in 3 patients, and supraclavicular lymph nodes in 4; 
pulmonary metastases occurred in 7, and liver metastases in 
1 patient. Definitive diagnosis was based on histopathological 
analysis of the operative specimen in all cases. The histological 
types seen were seminoma (8), embryonal carcinoma (8), 
teratoma (5) and mixed (3) (Fig. 3).
Treatment
Radical orchidectomy and cisplatin-based chemotherapy 
was the most common treatment combination, and was done 
in 11 (46%) patients; radical orchidectomy only and radical 
orchidectomy with radiotherapy in 6 (25%) patients each; and 
laparotomy, excision of intra-abdominal testicular tumour 
and chemotherapy was done in 1 (4%) patient. Surgical 
complications included surgical site infection in 4 patients and 
adhesive small-bowel obstruction in the patient with intra-
abdominal testes.
Retroperitoneal lymph node dissection (RPLND) was not 
done on any of our patients as they refused consent after being 
informed of the ejaculatory difficulty that might follow. The 
reason behind these refusals was fear of infertility, which has 
strong cultural and social consequences in Africa.
 
 
 
 
 
 
 
Fig. 1. Age distribution of patients. 
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Fig. 1. Age distribution of patients.
Table II. Tumour stage of 24 patients with testicular cancer
Stage 1     2 patients  8.3%
Stage 2     7 patients  29.2%
Stage 3     7 patients  29.2%
Stage 4     8 patients  33.3%
Total     24 patients  100%
Table I. Royal Marsden Hospital staging of testicular 
cancer
Stage
I  No evidence of metastasis
IM   Rising concentrations of serum markers 
with no other evidence of metastasis
II  Abdominal node metastases
A     <2 cm in diameter
B     2 - 5 cm diameter
C     >5 cm diameter
III  Supradiaphragmatic nodal metastasis
M  Mediastinal
N  Supraclavicular, cervical or axillary
O  No abdominal node metastases
ABC  Node stage as defined in stage II
IV
Lung
L1  <3 metastases
L2  ≥3 metastases, <2 cm diameter
L3   ≥3 metastases, one or more of which is  
>2 cm diameter
Stage IV subgroups include H+ (liver metastases), Br+ (brain metastases), Bo+ (bone 
metastases).
 
 
Fig. 2. Laterality of testicular c ncer
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Fig. 3. Histology of testicular cancer. 
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Cisplatin-based combination chemotherapy using the BEP 
regimen (bleomycin, etoposide, cisplatin) was commenced 7 - 
14 days postoperatively in 10 patients, while 2 patients with 
scrotal skin involvement received neo-adjuvant BEP to achieve 
tumour mobility and resectability.
The detailed dosage regimen used was: bleomycin 15 mg as 
a 24-hour infusion on days 2 and 3; etoposide 100 mg/m2 
intravenously on days 1 - 5; and cisplatin 120 mg/m2 as a 
2-hour infusion with diuresis and hydration on day 4. Four 
cycles were given at 3-weekly intervals. These intervals 
were sometimes extended to allow correction of anaemia, 
leucopenia and thrombocytopenia. Chemotherapy-induced 
nausea and vomiting were managed by methylprednisolone, 
metoclopramide and, in the later years of the study (from 
1999 to 2003 specifically), 5-HT3 antagonists. Four cycles 
were chosen as the recommended minimum for all patients to 
compensate for probable under-staging of our patients, owing 
to the unavailability of CT scanning.
In all, 12 patients received chemotherapy for a minimum 
of 3 courses, though these were often irregular as the patients 
had to buy the drugs, which they usually could ill afford, and 
no health insurance scheme existed at the time. Chemotherapy 
complications frequently encountered were stomatitis and 
haematological. We noted a single case of bleomycin-induced 
pneumonitis which resolved with conservative management. 
When a national health insurance scheme started, its coverage 
was only for contributors’ primary health problems, excluding 
cancer care.
The 6 patients who received radiotherapy were referred to 
centres in other cities where the facility was available, each 
at least 600 km away. Another 4 patients failed to receive the 
recommended radiotherapy because of the prohibitive distance 
to the radiotherapy centres and the costs involved.
Outcomes
Five patients died within 19 months of presentation and initial 
treatment response; all had stage 3 disease. Three failed to 
receive the recommended radiotherapy and re-presented in a 
moribund condition, while 2 had received 1 cycle of BEP only. 
The causes of death were superior vena cava obstruction (1), 
massive bilateral pleural effusion (2) and pulmonary embolism 
(2).
We defined loss to follow-up as any patient not seen for up 
to 3 years after presentation and treatment. Twelve patients 
were lost to follow-up, some as early as 3 months after our 
primary intervention. Seven patients were alive and well at 
3 years and beyond. The mean duration of follow-up was 9 
months. Only 3 patients were available for follow-up and well 
after 5 years.
Discussion
The peak age incidence of 20 - 29 (mean 28.1) years is 
consistent with other findings.7-10 However, the distribution 
of the stages in our series differed markedly from that in the 
developed world. In developed countries, stage 1 disease is the 
most common and also shows a consistent rise,7,11,12 whereas 
in our study stages 3 and 4 were the most common. The mean 
interval between onset of symptoms and presentation to a 
health care facility was unduly long (5.2 months, range 1 - 12 
months). Late presentation is thought to be due to ignorance, 
fear of consequences,13 long distances to hospitals, and strong 
beliefs in traditional medicine and religious charlatans.14 The 
most common presenting symptom was testicular swelling, 
which is in agreement with another African study.10
An undescended testis and abdominal mass was found 
in one (4%) patient, which is similar to  a 35-year review at 
Ibadan, Nigeria, where 4% of tumours arose from undescended 
testes.15 Our histological distributions of tumours are in 
agreement with studies from Lagos,9 where the most common 
tumours were embryonal carcinoma and seminoma, and from 
Nairobi, Kenya,10 where the most common type was seminoma. 
These findings suggest a similarity in histological patterns 
between Nigeria (West Africa) and Kenya (East Africa), but the 
small number of cases does not allow firm conclusions.
Given the small number of testicular cancer, inter-
institutional collaborative studies among countries will help 
to gain data for larger numbers of patients and so determine 
racial, inter-regional and temporal trends. However, this has 
not been the case in Nigeria; to our knowledge, only single-
centre studies have been published.
The treatment of testicular cancer consists of radical 
orchidectomy, cisplatin-based chemotherapy radiotherapy, and 
retroperitoneal lymph node dissection (RPLND). RPLND was 
not performed on any of our patients owing to their refusal 
of consent after information regarding ejaculatory difficulty 
was given. This is a setback to effective treatment, which can 
be remedied by better patient education. Consent for radical 
orchidectomy was often given reluctantly as patients perceived 
the procedure as emasculating, and a threat to manhood, 
sexuality and fertility.
In our series, radical orchidectomy was performed on 
all patients. Laparotomy (for excision of a malignant intra-
abdominal testis) was done on 1 patient. Surgical complications 
were limited to surgical site infection and an adhesive small-
bowel obstruction that resolved with conservative management 
in the patient who underwent laparotomy.
Twelve patients received chemotherapy, although this was 
irregular in most instances because of difficulties in sourcing 
the drugs, especially cisplatin, from abroad. Other difficulties 
included the high cost of the drugs, which patients had to bear 
as there was no health insurance scheme in the country at the 
time. When a health insurance scheme was initiated, it had a 
contributory basis, i.e. only salary earners in the public and 
private sector (comprising less than 10% of the population) 
were entitled to care, which does not include treatment of 
malignancies. This invariably means that patients have to fund 
treatment from meagre personal savings and the goodwill of 
relatives and friends. Another problem is the formal admission 
each time a patient requires chemotherapy owing to the lack of 
a dedicated chemotherapy unit that could offer chemotherapy 
on a day-care basis and provide home follow-up care.
Our mean duration of follow-up was 9 months. After 24 
months, 12 (50%) of our patients were lost to follow-up. A high 
incidence of loss to follow-up is common in the developing 
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world.16 Poverty, ignorance and, possibly, poor doctor-patient 
communication may be factors. Radiotherapy facilities were 
not available in our centre (or anywhere in south-eastern 
Nigeria) during the study period, and patients had to travel 
to other centres, each at least 600 km from our centre. This 
usually separated patients from their support base of family 
and friends and affected their psyche negatively, and often led 
to delays in commencing radiotherapy. The long distances also 
resulted in non-completion of radiotherapy in many cases, as 
patients often had to return home to acquire more funds from 
relatives and friends.
Testicular cancer has excellent survival figures in the 
developed world, approaching 97% for low-stage disease.17 
In our series, however, the outcome was poor, with 5 patients 
dead within 19 months of presentation and 12 (half) of our 
patients lost to follow-up within 24 months. Only 3 patients 
were followed up for 5 years. Possible reasons for this poor 
outcome and, more importantly, the dismal follow-up periods, 
include late presentation, ignorance, and inadequate patient 
education regarding the value of follow-up in malignancy even 
when symptoms are absent. Paucity of resources for tracing 
patients and home visits is common in our public hospitals.
Conclusion
The management of testicular cancer in our environment 
includes challenges such as late presentation, high-stage 
disease at presentation, absence of radiotherapy facilities in 
south-eastern Nigeria, high cost of drugs, and virtually zero 
patient awareness of testicular self-examination. A holistic 
approach is advocated, including a significant increase in 
health care funding, expansion of the health insurance scheme 
to cover cancer treatment, improved patient education, and 
an emphasis on home visits to follow up such patients. The 
inclusion of teaching testicular self-examination into the 
primary and secondary school curriculum is also proposed as a 
preventive strategy.
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